+

WO2006030211A3 - Sulfamides acycliques - Google Patents

Sulfamides acycliques Download PDF

Info

Publication number
WO2006030211A3
WO2006030211A3 PCT/GB2005/003551 GB2005003551W WO2006030211A3 WO 2006030211 A3 WO2006030211 A3 WO 2006030211A3 GB 2005003551 W GB2005003551 W GB 2005003551W WO 2006030211 A3 WO2006030211 A3 WO 2006030211A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
het
alkenyl
hydrogen
amino
Prior art date
Application number
PCT/GB2005/003551
Other languages
English (en)
Other versions
WO2006030211A2 (fr
Inventor
Christopher John Hobbs
Rosemary Lynch
Sarah Louise Mellor
Fleur Radford
Jenny Christine Gilbert
Stephen Stokes
Angela Glen
Andrea Fuimana
Christopher Geoffrey Earnshaw
Lars Jacob Stray Knutsen
Kathryn Elizabeth Sorrel Dean
Original Assignee
Vernalis R&D Ltd
Christopher John Hobbs
Rosemary Lynch
Sarah Louise Mellor
Fleur Radford
Jenny Christine Gilbert
Stephen Stokes
Angela Glen
Andrea Fuimana
Christopher Geoffrey Earnshaw
Lars Jacob Stray Knutsen
Kathryn Elizabeth Sorrel Dean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd, Christopher John Hobbs, Rosemary Lynch, Sarah Louise Mellor, Fleur Radford, Jenny Christine Gilbert, Stephen Stokes, Angela Glen, Andrea Fuimana, Christopher Geoffrey Earnshaw, Lars Jacob Stray Knutsen, Kathryn Elizabeth Sorrel Dean filed Critical Vernalis R&D Ltd
Publication of WO2006030211A2 publication Critical patent/WO2006030211A2/fr
Publication of WO2006030211A3 publication Critical patent/WO2006030211A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a remarqué que des composés représentés par la formule (I) ont un effet antagoniste sur les canaux calciques de type N. Dans la formule, A représente une fraction hétéroaryle ou hétérocyclyle de 5 à 10 chaînons, cette fraction étant éventuellement fusionnée à un phényle, un hétéroaryle à 5 ou 6 chaînons, un carbocyclyle C3-C6 ou un groupe hétérocyclyle à 5 ou 6 chaînons; B représente une liaison ou une fraction alkyle C1-C6 ou alcényle C2-C6; soit (a) R1 représente hydrogène ou alkyle C1-C6 et R2 représente hydrogène, alkyle C1-C6, alcényle C2-C6, halogène, hydroxy, thio, amino, -Het-L ou -L-Het-L', où L et L' sont identiques ou différents et représentent alkyle C1-C6 ou alcényle C2-C6 et Het représente O, S ou NR, où R représente hydrogène ou alkyle C1-C6, soit (b) R1 et R2 forment, ensemble avec le carbone auquel ils sont liés, une fraction carbocyclyle C3-C8 ou hétérocyclyle de 5 à 10 chaînons; R3 représente hydrogène, alkyle C1-C6, alcényle C2-C6 ou -L-Het-L', dans lequel L, L' et Het sont tels que définis ci-avant; et - R4, R5 et R6 sont identiques ou différents et représentent hydrogène, halogène, hydroxy, amino, thio, alkyle C1-C6, alcényle C2-C6, alcoxy C1-C6, alkylthio C1-C6, mono alkyle C1-C6 amino ou dialkyle C1-C6amino. Formule (I)
PCT/GB2005/003551 2004-09-14 2005-09-14 Sulfamides acycliques WO2006030211A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420424.4 2004-09-14
GB0420424A GB0420424D0 (en) 2004-09-14 2004-09-14 Therapeutic compounds

Publications (2)

Publication Number Publication Date
WO2006030211A2 WO2006030211A2 (fr) 2006-03-23
WO2006030211A3 true WO2006030211A3 (fr) 2006-06-01

Family

ID=33306547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003551 WO2006030211A2 (fr) 2004-09-14 2005-09-14 Sulfamides acycliques

Country Status (2)

Country Link
GB (1) GB0420424D0 (fr)
WO (1) WO2006030211A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (fr) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzènesulfonamides et leur emploi en tant qu'agents bloquants des canaux calcium
WO2008124118A1 (fr) 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
WO2009040659A2 (fr) 2007-09-28 2009-04-02 Purdue Pharma L.P. Composés benzènesulfonamides et leurs utilisations
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405391A1 (fr) * 1989-06-28 1991-01-02 Ciba-Geigy Ag Certains acides (arylsulfonamido- et pyridyl- ou imidazolyl-)carboxyliques substitués et leurs dérivés
WO1996005201A1 (fr) * 1994-08-10 1996-02-22 British Biotech Pharmaceuticals Limited Derives d'imidazopyridine utilises comme antagonistes du facteur d'activation plaquettaire (paf) et de la double histamine (h1)
WO1999031061A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
WO2001004087A1 (fr) * 1999-07-13 2001-01-18 Eli Lilly And Company Limited Derives benzylamine substitues de sulfonamides et leur utilisation comme medicaments
WO2003082873A1 (fr) * 2002-04-01 2003-10-09 Almirall Prodesfarma, S.A. Nouveaux derives de 4-(pyrrolopyrimidin-6-yl)benzenesulphonamide
WO2005068448A1 (fr) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides a action antagoniste sur des canaux calcium de type n

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405391A1 (fr) * 1989-06-28 1991-01-02 Ciba-Geigy Ag Certains acides (arylsulfonamido- et pyridyl- ou imidazolyl-)carboxyliques substitués et leurs dérivés
WO1996005201A1 (fr) * 1994-08-10 1996-02-22 British Biotech Pharmaceuticals Limited Derives d'imidazopyridine utilises comme antagonistes du facteur d'activation plaquettaire (paf) et de la double histamine (h1)
WO1999031061A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
WO2001004087A1 (fr) * 1999-07-13 2001-01-18 Eli Lilly And Company Limited Derives benzylamine substitues de sulfonamides et leur utilisation comme medicaments
WO2003082873A1 (fr) * 2002-04-01 2003-10-09 Almirall Prodesfarma, S.A. Nouveaux derives de 4-(pyrrolopyrimidin-6-yl)benzenesulphonamide
WO2005068448A1 (fr) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides a action antagoniste sur des canaux calcium de type n

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. SOYKA ET AL: "6,6-Disubstituted Hex-5-enoic Acid Derivatives as Combined Thromboxane A2 Receptor Antagonists and Synthetase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 1, 1994, pages 26 - 39, XP002374839 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds

Also Published As

Publication number Publication date
WO2006030211A2 (fr) 2006-03-23
GB0420424D0 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
WO2006030211A3 (fr) Sulfamides acycliques
JO2668B1 (en) Isoczazolins for controlling invertebrate insects
WO2007048065A3 (fr) Pyrimidinones en tant que modulateurs de caseine kinase ii (ck2)
WO2008105442A1 (fr) Dérivé de sulfonamide
WO2008114817A1 (fr) Nouveau composé d'adénine
TW200624421A (en) Method for preparing n-phenylpyrazole-1-carboxamides
WO2004013120A8 (fr) Nouveaux benzodioxoles
WO2006032466A3 (fr) Nouveaux antibiotiques bicycliques
TNSN08269A1 (en) Derives de pyrimidine
WO2005044793A3 (fr) Composes heterocycliques accoles contenant de l'azote
WO2008057855A3 (fr) Modulateur du récepteur de glucocorticoïdes, ap-1, et/ou activité de nf-kb et leur utilisation
TW200626559A (en) Anilino-pyrimidine analogs
WO2009014100A1 (fr) INDUCTEUR DE PROTÉINE p27
MXPA05008584A (es) Compuestos heterociclicos utiles como activadores de nurr-1.
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
PL1904482T3 (pl) Pochodne indolilomaleimidowe
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
WO2003064429A1 (fr) Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
WO2005105096A3 (fr) Composes heterocycliques fusionnes
WO2007057265A3 (fr) Composes triazine a substituants contenant des groupes amino et des groupes carboxy
EP1553096A4 (fr) Composes pyrazole
WO2007147847A3 (fr) Compositions thermochromes réversibles
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载